Japan Daily Briefing

Kioxia delivered one of Japan's strongest quarterly semiconductor results in years with ¥1.27 trillion in Q1 operating profit — a figure that validates the NAND flash pricing recovery thesis and signals the AI-driven memory upgrade cycle is driving volumes well beyond base storage. Management guided for further Q2 expansion and is pursuing Long-Term Agreements (LTAs) with hyperscaler customers to lock in demand visibility. For investors tracking the Japan semicap supply chain — Tokyo Electron, Advantest, Disco — Kioxia's numbers confirm their capital equipment orders will stay elevated through H2 2026. The self-buyback announcement adds shareholder return credibility to a result that already has fundamental momentum.

Takeda Pharmaceutical's Q1 2026 earnings call confirmed that Japan's major pharmaceutical sector is navigating a complex cycle: patent-cliff headwinds on legacy drugs offset by pipeline progress in oncology and rare diseases. For BoJ normalization watchers, Takeda is a useful bellwether — its large USD-revenue exposure means a stronger JPY reduces reported earnings, while a weaker yen (current dynamic) provides translation tailwinds. The Q1 result gives the Japan pharma basket a near-term data point ahead of what's expected to be a more eventful H2.

Today's 50bps hedged-vs-unhedged Japan equity return differential implies USD/JPY continued its run above 155 without triggering BoJ verbal intervention. The silence is itself a signal: at prior JPY weakness episodes the BoJ or MOF issued commentary around 155-157 to curb volatility. Today's non-event suggests the policy stance has shifted toward tolerance of a weaker yen, particularly as BoJ's rate normalization path remains gradual. For Nikkei-tracking investors, a USD/JPY above 155 supports exporters (Toyota, Honda, Sony) and adds FX carry for international investors in Japanese equities — the fundamental driver of the hedged-outperformance gap.